Bellerophon Therapeutics is a clinical-stage biotherapeutics company. We are focused on developing innovative therapies in the treatment of cardiopulmonary diseases. Our mission is to develop well-studied molecules deployed through innovative delivery systems to treat diseases with significant unmet clinical need. More … Continued
Location: United States, New Jersey
Investors 2
| Date | Name | Website |
| - | 5AM Ventur... | 5amventure... |
| 17.07.2021 | ARCH Ventu... | archventur... |
Mentions in press and media 5
| Date | Title | Description |
| 06.03.2023 | Bellerophon Therapeutics Announces $5 Million Registered Direct Offering | - |
| 02.04.2020 | ARCH Venture, Flagship Pioneering close funds worth nearly $2.6B | ARCH said it would use its two funds to invest in early-stage companies. Although it plans to frequently draw from both to invest in a single company, the overage fund will be used in fewer deals that require larger investments. “ARCH is st... |
| 20.03.2020 | Bellerophon Therapeutics Gets FDA Emergency Approval for INOpulse to Treat COVID-19 | - |
| 13.02.2015 | Bellerophon prices $60m IPO low, issues more shares | Bellerophon Therapeutics (NSDQ:BLPH) priced its initial public offering under range today but offered more shares than planned, for total proceeds of $60 million. Hampton, N.J.-based Bellerophon had planned to raise up to $69 million by put... |
| - | ARCH Venture, Flagship Pioneering close funds worth nearly $2.6B | Two large venture capital firms have raised nearly $2.6 billion that they plan to invest in life sciences startups, they said in announcements Thursday. Cambridge, Massachusetts-based Flagship Pioneering said it had closed a $1.1 billion ca... |